Background {#Sec1}
==========

Bipolar disorder (BD) is a major psychiatric illness with a complex multifactorial etiology. Twin and adoption studies underscore the importance of inherited factors, and association studies, including genome-wide association studies by large consortia, have reported some replicable loci, notably *CACNA1C*, *ODZ4*, and *NCAN* (Cichon et al. [@CR6]; Psychiatric GWAS Consortium Bipolar Disorder Working Group [@CR52]). Despite the large sample sizes, family history in a close relative is still the best genetic prediction method for BD, and other molecular methods may be helpful to address the genetics of non-Mendelian disorders (Craddock and Sklar [@CR8]; Schulze [@CR55]).

In addition to genetic studies, discordance for BD in monozygotic (MZ) twins (Bertelsen et al. [@CR3]; Sklar et al. [@CR58]; McGuffin et al. [@CR40]; Kieseppa et al. [@CR28]) invites speculation about environmental risk factors. Evidence is suggestive of a role for environment in the genesis and course of BD (Serretti and Mandelli [@CR57]). Prospective studies implicate psychosocial and other environmental variables in the timing of BD mood episodes (Proudfoot et al. [@CR50]). Other data indicates that at least one third of adults with a BD diagnosis report childhood trauma, which is associated with more difficult course of illness (Leverich and Post [@CR36]). Yet the specific role of environment remains unclear. Stressful life events are associated with BD, but robust evidence of a cause-effect relationship is lacking (Miklowitz and Chang [@CR41]). And overall, environment plays a lesser role in the risk for developing the illness (McGuffin et al. [@CR40]). Thus, despite the significant effort, much remains to be understood about the genetic and environmental basis of BD.

In recent years, epigenetic factors have become an avenue of investigation with some promise (Labrie et al. [@CR33]), with the complex epigenetic regulation of *Bdnf* showing relevance to psychiatric disorders and environment (Boulle et al. [@CR4]). Numerous clinical and epidemiological features of BD can be explained by epigenetic misregulation. Epigenetics refers to regulation of various genomic functions that are controlled by heritable, partially stable modifications in DNA methylation and/or chromatin structure (Henikoff and Matzke [@CR21]). Epigenetic studies in twins have detected a large degree of MZ co-twin DNA methylation variation (Petronis et al. [@CR49]; Kaminsky et al. [@CR25]), which may contribute to the MZ twin discordance observed in BD. Putative epigenetic misregulation is also consistent with variable age of onset, fluctuating clinical course with exacerbations and remissions, peaks of susceptibility coinciding with hormonal changes, parent-of-origin effects, and sexual dimorphism (Arnold et al. [@CR1]).

Epigenetics gives additional framework for understanding the function of genome sequence and genetic complexity. Ambiguous genetic results on complex disease phenotypes could be more salient if considered in an epigenomic context (Feinberg [@CR14]). In aggregate, such findings have led to the notion that epigenetic factors may be relevant to complex non-Mendelian phenotypes like BD (Labrie et al. [@CR33]; Petronis [@CR48]) and may account for a fraction of the 'missing heritability' of complex traits (Maher [@CR39]).

Several lines of evidence link brain-derived neurotrophic factor (BDNF) to BD. Serum BDNF levels are reduced in depression (Molendijk et al. [@CR43]), euthymic BD (Monteleone et al. [@CR44]), acute mania (Machado-Vieira et al. [@CR38]; Tramontina et al. [@CR61]), and bipolar depression (Fernandes et al. [@CR15]) and are lower with longer duration of illness (Kauer-Sant\'Anna et al. [@CR26]). A meta-regression has confirmed that serum/plasma BDNF levels are consistently reduced during manic and depressive episodes and are restored to normal levels in subjects treated for acute mania (*n* = 1,113 subjects) across 13 studies (Fernandes et al. [@CR16]). From genetics reports, polymorphisms within the BDNF gene have been studied in BD (Neves-Pereira et al. [@CR46]; Sklar et al. [@CR58]). There is a frequently cited association between BD and the SNP rs6265, also known as the Val66Met variant. Association of SNP rs6265 has been repeatedly shown with BD and was statistically significant in a meta-analysis of 14 studies comprising of 4,248 cases, 7,080 controls, and 858 nuclear families (Fan and Sklar [@CR13]). More recently, rs6265 Met allele carriers were observed to have different serum BDNF profiles during a period of treatment than Val allele homozygotes (Grande et al. [@CR19]).

A limited number of studies have been conducted to investigate DNA modifications at *BDNF* in BD, and most were done on postmortem brain tissue. Among them, a comprehensive study showed cytosine-guanine dinucleotide (CpG) DNA methylation variation in BD patients in proximity of the *BDNF* SNP rs6265; exonic CpG methylation was associated with the valine variant of rs6265 in a sample of 105 postmortem brains (Mill et al. [@CR42]). In another study, Rao et al. ([@CR53]) demonstrated increased methylation of *BDNF* promoter 1 in frontal cortex tissue in ten BD brains compared to ten age-matched controls (*p* \< 0.05). Hypermethylation at *BDNF* promoter 1 in peripheral blood monocyte DNA has also been reported in 16 participants with Bipolar II Disorder (BD-II) (*p* \< 0.01) but not for 16 participants with Bipolar I Disorder (BD-I) when compared to controls; the investigators also observed that lithium and valproate reduce promoter 1 DNA methylation (D\'Addario et al. [@CR9]).

The evidence reviewed above suggests a putative role for the *BDNF* locus in BD. Our aim was to characterize epigenetic regulation of *BDNF* in peripheral blood, and our hypothesis was that BD patients exhibit *BDNF* promoter methylation differences compared to controls.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Participants consisted of 50 randomly selected BD cases and 50 unrelated healthy controls matched for age and sex from a larger sample (*n* = 452 BD cases) as previously described (Scott et al. [@CR56]; Psychiatric GWAS Consortium Bipolar Disorder Working Group [@CR52]). Inclusion criteria were as follows: (a) diagnosed with DSM-IV or ICD-10 BD-I or II, (b) age 18 years old or above, and (c) Caucasian, of Northern and Western European origin. Exclusion criteria includes the following: (a) diagnosis of intravenous drug dependence or reported use of intravenous drugs, (b) evidence of mental retardation, (c) related to an individual already in the study, (d) manias *that only* ever occurred in relation to or as a result of alcohol or substance abuse or dependence, medications, and/or medical illness, and (e) had mood-incongruent psychotic symptoms. BD diagnoses were established according to DSM-IV or ICD-10 criteria, using the computerized algorithm (CATEGO) for the SCAN 2.1 interview (WHO) (Celik [@CR5]). Our investigation was completed in compliance with the Declaration of Helsinki and was approved by the Research Ethics Board of the Centre for Addiction and Mental Health.

### Clinical and demographic characteristics {#Sec4}

Fifty randomly selected cases were included. All cases selected had BD-I; none of the 50 randomly selected cases had BD-II. All participants were of northern European ancestry. They were equal with equal numbers of males and females. Cases and controls were matched for sex and age. Mean ages at phlebotomy (SD) for cases and controls were 45.3 (12.4) and 45.4 (12.4) years, respectively.

Genomic DNA extraction {#Sec5}
----------------------

Venous blood was collected in Toronto at the Centre for Addiction and Mental Health and preserved in ethylenediaminetetraacetic acid (1.8 mg EDTA/mL of blood). DNA was extracted using a high salt method (Lahiri and Nurnberger [@CR34]). Quantity and quality of genomic DNA was estimated on nanodrop spectrophotometer (Nanodrop Products, Wilmington, DE, USA), and genomic DNA with 260/280 ratio \>1.8 and 260/230 \>1.9 was taken for downstream analysis.

Estimation of *BDNF* promoter DNA methylation {#Sec6}
---------------------------------------------

*BDNF* sequence (AF411339.1) was used to map different known CpG promoters within the gene (Figure [1](#Fig1){ref-type="fig"}); two methods were used. First, the CSHL human promoter mapping using CpG islands (CpGpromoter) (Ioshikhes and Zhang [@CR23]) enabled mapping of human promoters using Gardiner-Garden and Frommer\'s definition of CpG islands (Gardiner-Garden and Frommer [@CR18]) (<http://rulai.cshl.org/tools/CpG_promoter>). CpGpromoter indicated CpG islands related to promoters at three regions of AF411339.1. Second is the BIMAS Promoter Scan (Center for Information Technology, NIH, <http://www-bimas.cit.nih.gov/molbio/proscan/>), which uses PROSCAN 1.7 to predict promoters based on scoring homologies with eukaryote Pol II sequences. BIMAS corroborated the three CpG island promoters noted with CpGpromoter, which correspond to *BDNF* promoters 1, 3, and 5 of the nine promoters described by Pruunsild et al. ([@CR51]) (see Figure [1](#Fig1){ref-type="fig"}).Figure 1**Graphical overview at BDNF gene.** The BDNF gene structure and promoter locations are adopted from the study of Pruunsild et al. ([@CR51]). Arrow on the top shows the direction of BDNF transcript; exons (green), CpG islands (cyan), and investigated regions for DNA methylation (black) are mapped on NCBI accession number AF411339.1. CpG island were detected by CpGPlot using default parameters (<http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/>). Number of CpG dinucleotides in each amplicons is shown as lollipops on the lower panel.

Bisulfite conversion was performed on 500 ng of genomic DNA using the QiagenEpiTect Kit, Hilden, Germany, according to the manufacturer's protocol. Primers were then designed on these promoters, and in total, three amplicons were generated covering 30 CpG sites at promoter 3 and 42 CpG sites at promoter 5.

Multiple attempts and different primer pairs in our hands failed to amplify any region at promoter 1. Bisulfite primers and polymerase chain reaction (PCR) amplification conditions are stated in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

The amplified fragments were analyzed on a MassARRAY platform (Sequenom, San Diego, CA, USA) at the Clinical Genomics Centre in Toronto (<http://www.clinicalgenomics.ca/>). Locus-specific PCR amplification was performed with the T7-promoter tagged primers, where the latter was used to generate *in vitro* transcription on the amplified fragments. These transcripts were then subjected to enzymatic RNA base pair cleavage. The resulting fragments differ in size and mass depending on the sequence changes generated through bisulfite treatment. The fragment mass was determined by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry; then, EpiTYPER software converted MALDI-TOF (Ehrich et al. [@CR12]) values to quantitative percent of CpG dinucleotide methylation. The method reads small DNA fragments for mass-to-charge ratio, and these small reads may map to multiple CpG sites on the same amplicon; hence, often two or three CpG sites have one measured value. The resulting analytic units are called *CpG units* which consist of a single CpG site or a combination of two or three CpG sites. Methylation measures were performed in triplicate expressed as a methylation fraction (range 0 to 1) for each CpG.

Additional exploratory analyses of *BDNF* promoter methylation by *BDNF* rs6265 (i.e., Val66Met) genotype were conducted to investigate possible interaction effects. Genotyping with Illumina HumanHap550 BeadChip, Illumina Inc., San Diego, CA, USA, and quality control methods were as previously described (Scott et al. [@CR56]). Specifically, individual CpG unit methylation was tested for association with BD in two genotype groups: A (rare) allele carriers consisting of AG and AA genotypes and G (common) allele homozygotes.

Statistical analysis {#Sec7}
--------------------

Univariate statistics were performed for demographic and clinical characteristics of BD patients and control individuals. The means of the triplicate methylation fractions (MMFs) were examined, only the readouts with standard deviations \< 0.15; therefore, 8 of 72 CpG sites were excluded for a total of 64 CpGs comprising 36 CpG units. Since 15 of 36 CpG units had significant differences in homogeneity of variances, the nonparametric Mann--Whitney test was used for differences in mean methylation fractions (in both Table [1](#Tab1){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}: Table S2). We tested age and sex for association with DNA methylation and corrected for multiple testing with false discovery rate (FDR) (Benajmini and Hochberg [@CR2]) for 36 CpG units, yielding a significance threshold of alpha = 0.004.Table 1**Mean methylation fractions for BDNF CpG units in bipolar disorder versus controls**AmpliconCpG unitBP MMF (SD)Controls MMF (SD)***Z***Asymp. sig.Cohen\'s ***d***D2a1, 20.354 (0.077)0.335 (0.067)−1.7120.08711, 260.156 (0.025)0.159 (0.038)−0.0610.95112, 13, 140.301 (0.030)0.289 (0.034)−1.8640.062150.103 (0.022)0.100 (0.026)−0.6820.495160.086 (0.012)0.082 (0.015)1.7970.072170.122 (0.032)0.116 (0.015)−2.330.02\*18, 19, 200.242 (0.032)0.232 (0.035)−1.7890.072210.128 (0.014)0.126 (0.023)−0.4490.65422, 230.275 (0.018)0.260 (0.023)−2.0940.036\*240.089 (0.011)0.086 (0.028)−1.2170.22427, 28, 29, 300.246 (0.031)0.238 (0.014)−1.2840.19930.355 (0.034)0.333 (0.032)−3.315*0.001* ***\*\****0.68040.054 (0.025)0.048 (0.031)−1.0540.2925, 60.279 (0.047)0.274 (0.022)−0.7330.4649, 100.254 (0.034)0.255 (0.038)−0.2560.798D311, 12, 130.227 (0.014)0.217 (0.019)−2.889*0.004* ***\*\****0.610140.085 (0.011)0.079 (0.017)−2.370.018\*15, 16, 170.181 (0.016)0.163 (0.027)−2.993*0.003* ***\*\****0.840180.068 (0.012)0.061 (0.011)−3.179*0.001* ***\*\****0.610190.055 (0.011)0.056 (0.012)−0.1570.8752, 3, 40.284 (0.019)0.282 (0.020)−0.4840.628200.480 (0.068)0.504 (0.101)−0.7280.466210.021 (0.008)0.021 (0.015)−0.7280.46622, 23, 80.136 (0.008)0.126 (0.014)−3.8*\<0.001* ***\*\****0.9105, 60.316 (0.029)0.302 (0.054)−0.6010.54870.068 (0.011)0.066 ()0.016−0.7990.4249, 100.069 (0.009)0.066 (0.012)−2.0170.044\*D511, 12, 130.233 (0.030)0.220−1.9620.05\*140.065 (0.014)0.063−0.8530.394150.253 (0.085)0.253−0.1550.877160.093 (0.022)0.083−2.1190.034\*17, 18, 190.172 (0.017)0.160−2.4470.014\*4, 50.168 (0.097)0.200−1.090.27660.056 (0.017)0.057−0.3910.6967, 80.205 (0.021)0.1971.6710.09590.061 (0.048)0.074−1.350.177\*Significant at alpha = 0.05; **\*\***significant after FDR, alpha = 0.004; BP, bipolar disorder. MMF, mean methylation; *d,* effect size; Z, Mann Whitney U test statistic.

Results {#Sec8}
=======

Regional CpG promoter methylation {#Sec9}
---------------------------------

We examined DNA methylation for each CpG promoter region using the average of all CpG units mean methylation fractions (MMFs) in a *BDNF* region that we studied, in this case, the amplicons that were assayed. A significant difference in *BDNF* methylation between cases and controls for region/amplicon D3 (*Z* = −2.185, *p* = 0.029) was noted. The other two regions exhibited no significant case--control differences in DNA methylation, D2a (*Z* = −1.915, *p* = 0.055) or D5 (*Z* = −0.0417, 0.677). This was also evident at the individual CpG level of DNA methylation analysis (below), where the majority of significant CpG units were in region D3.

Methylation of individual CpGs {#Sec10}
------------------------------

### D2a amplicon {#Sec11}

Individual CpG units with nominal (*p* \< 0.05) case--control differences in MMF were CpG 17 (*Z* = −2.33, *p* = 0.02), CpG 22,23 (*Z* = −2.094, *p* = 0.036), and CpG 3 (*Z* = −3.315, *p* = 0.001. Cases were more methylated than controls; of these, only CpG 3 passed FDR correction).

### D3 amplicon {#Sec12}

Several CpG units demonstrated significance within this region. Four CpG units survived FDR, including CpG 11,12,13 (*Z* = −2.889, *p* = 0.004), CpG 15,16,17 (*Z* = −2.993, *p* = 0.003), CpG 18 (*Z* = −3.179, *p* = 0.001), and CpG 22,23,8 (*Z* = −3.8, *p* = 0.001). Two CpG units had nominally significant case--control differences in methylation, CpG 14 (*Z* = −2.37, *p* = 0.018) and 9,10 (Z = −2.017, *p* = 0.044); at each of the significant CpG units, cases had higher MMFs than controls.

### D5 amplicon {#Sec13}

Differences in methylation were nominally significant at CpG units 11,12,13 (*Z* = −1.962, *p* = 0.05), 16 (*Z* = −2.119, *p* = 0.034), and 17,18,19 (*Z* = −2.447, *p* = 0.014); none were significant after the FDR correction.

For CpG units which remained significant after FDR, differences in MMF ranged from 0.007 to 0.022, with Cohen\'s *d* ranging from 0.61 to 0.91. See Table [1](#Tab1){ref-type="table"}.

TFBS mapping {#Sec14}
------------

Next, we looked for the transcription factor binding sites (TFBSs) that are in proximity to significant individual CpG results. For this, we mapped the DNA sequences of the three *BDNF* amplicons for their TFBSs, using the transcription factor binding profile database JASPAR (<http://jaspar.genereg.net/>), and investigated the distance between CpGs having at least nominally significant group differences in DNA methylation and the nearest TFBS. At the D2a amplicon, CpG unit 17 showed GATA binding protein 2 and 3 (GATA2 and GATA3) TFBSs. For amplicon D3, CpG unit 15,16,17 showed a complete overlap with an AP-2 alpha (activating enhancer binding protein 2 alpha) (TFAP2A) (Comb and Goodman [@CR7]) binding site, and another TFAP2A site was within 3 bp downstream of CpG unit 22,23,8. Similarly, within amplicon D5, three TFBSs were at or within 15bp of CpGs: a TFAP2A site spans CpG unit 11,12,13; a myeloid zinc finger 1 (MZF1) TFBS was at CpG unit 17,18,19, and a nuclear factor-kappa B (NFKB1) (Rau et al. [@CR54]) TFBS was 15 bp downstream of CpG 17,18,19. The TFBSs above - GATA2, GATA3, TFAP2A, MZF1, and NFKB1 - are all expressed in brain and white blood cells.

Age, sex, and BDNF methylation {#Sec15}
------------------------------

The D2a amplicon showed a positive correlation between age at sample collection and MMF (rho = 0.56, *p* = 2.80 × 10^−5^) in BD cases, but no correlation was observed in controls (rho = 0.17, *p* = 0.25) (Figure [2](#Fig2){ref-type="fig"}). In contrast, no correlation of DNA methylation with age was observed for D3 or D5 amplicons. No sex effects on DNA methylation were observed in any of the three amplicons (see Figure [2](#Fig2){ref-type="fig"}).Figure 2**Correlation between age and CpG unit methylation.** Methylation at amplicon D2a is correlated with age in bipolar cases but not in controls. Black, BP cases (rho = 0.56, *p* = 2.80 × 10^−5^). Gray, controls (rho = 0.17, *p* = 0.25).

In summary, we found five CpG units in *BDNF* promoters with MMFs differing between BD and controls, predominantly in the D3 amplicon. We also observed positive correlation between age and MMF in D2a amplicon of promoter 3, significant in cases but not controls.

When testing for genotype group differences at individual CpG unit methylation sites, six CpG units were nominally significant (two in each of the three amplicons) at alpha = 0.05. With a slightly more stringent threshold of alpha = 0.01, six other CpG units remained significant, five of which were in amplicon D3. The preponderance of most significant *post hoc* methylation findings were with the rs6265 G or Val homozygotes at CpG sites that were significant after FDR in the initial BD control analysis (D2, CpG unit 3; D3, CpG units 11,12,13; 15,16,17; 22,23,8). See Additional file [2](#MOESM2){ref-type="media"}: Table S2.

Discussion {#Sec16}
==========

We examined three amplicons over two *BDNF* CpG promoters in 50 BD I participants and 50 age- and sex-matched controls. Of 36 CpG units, 6 CpG units differed nominally in MMF between cases and controls; 5 CpG units' MMFs, mostly in amplicon D3 (promoter 5), remained significant following FDR. Effect sizes were medium to large (0.61 to 0.91) at CpG units significant after FDR, while absolute differences in methylation fraction were small (0.002 to 0.022). We noted that several of these significant CpG units were at or in the immediate vicinity of TFBSs. We also observed a statistically significant correlation between the participant\'s age and DNA methylation for D2a (promoter 3) in the cases; however no correlation was found for the controls. The majority of findings published to date have been on other promoters, unlike ours, which focused on promoters 3 and 5. The age promoter 3 methylation correlation was less strong when cases and controls were pooled (rho = 0.353; *p* = 0.00036) but still significant.

Earlier investigations have examined *BDNF* methylation in affected brain tissues. In *postmortem* tissue from Wernicke\'s area, four CpG dinucleotides in the *BDNF* promoter 4 area had elevated methylation in suicide cases compared to controls (Keller et al. [@CR27]). Another *postmortem* brain study reported *BDNF* promoter hypermethylation in frontal cortex tissue in BD (Rao et al. [@CR53]), in accord with the same group\'s previous finding of reduced *BDNF* mRNA in Brodmann area 9 of BD brains (Kim et al. [@CR29]). The investigators examined several loci in the same region in BD and Alzheimer\'s disease, including 81 CpG sites in *BDNF* promoter 1. Our findings differ not only in the tissue of interest but also in the promoters assayed.

A limited number of studies have focused the DNA methylation analysis at *BDNF* promoters using blood-derived DNA in psychiatric or addiction patients. For example, maternal prenatal smoking has been shown to increase methylation of *BDNF* exon 6 in adolescent offspring (Toledo-Rodriguez et al. [@CR60]). In major psychosis patients, *BDNF* promoter 1 was hypermethylated in peripheral blood monocytes for BD-II but not for BD-I; again, we did not assay promoter 1 and have no methylation data on BP-II for the current report. Influence from medication has also been reported: antidepressants were associated with increased methylation, while mood stabilizers were associated with reduced methylation (D\'Addario et al. [@CR9]). The CpG units that were significant in our investigation had cases with higher MMFs than controls. *BDNF* promoter 1 DNA methylation signals were also reported for unipolar major depressive disorder patients; a small number of CpG units demonstrated several fold increase or decrease in methylation in cases versus controls by mass spectrometry and subsequent hierarchical cluster analysis, generating *p* values smaller than 10^−11^ (Fuchikami et al. [@CR17]). Other studies have recently demonstrated higher degrees of methylation in the *BDNF* region to be associated with other mood-related phenotypes such as poststroke depression (Kim et al. [@CR30]) and antidepressant response (Tadić et al. [@CR59]).

Association of age with DNA methylation, including promoter methylation, is well documented (Jaenisch and Bird [@CR24]; Kwabi-Addo et al. [@CR32]; Vasilatos et al. [@CR62]; Liu et al. [@CR37]). Human prefrontal cortex genomic DNA has age-related dynamic methylation at several gene promoters (Numata et al. [@CR47]). DNA methylation in blood cells was also reported to correlate with age and local sequence features (Langevin et al. [@CR35]). Some studies conflict or suggest that methylation-age associations are tissue- and locus-dependent (Eckhardt et al. [@CR11]; Heijmans et al. [@CR20]). We noted a positive correlation between age and CpG methylation in *BDNF* promoter 3, only for the BD cases. Serum BDNF concentrations have been negatively correlated with age (Kauer-Sant'Anna et al. [@CR26]). Taken together, such findings suggest that a reduction in BDNF expression with age might be associated with increased methylation observed at promoter 3.

Some limitations in the present study require acknowledgement. First, we opted for an agnostic *in silico* approach for CpG promoter detection with CpGpromoter and BIMAS and investigated a few promoters. There are nine known *BDNF* promoters. We created primers for three (promoters 1, 3, and 5 for reasons explained above and immediately below), one of which (promoter 1) was not completed due to technical issues. Promoters other than 1, 3, and 5 did not score as highly on the in silico scans.

Our laboratory method for DNA methylation investigation exploits mass spectrometry, which is a precise technique that detects very small DNA methylation differences (to 14 kDa). This highly sensitive method was used to assay candidate CpG units from peripheral blood DNA and hence requires validation for DNA methylation differences in the affected tissue, i.e., *postmortem* brain. While some evidence points to differences between blood, cortical, and cerebellar methylation for several neurodevelopmental genes, including *BDNF* (Davies et al. [@CR10]), generally, *BDNF* methylation shows consistency across brain and blood (Ikegame et al. [@CR22]). Still, a growing number of analyses based on leukocyte-derived DNA methylation in psychiatric disorders exist, including a study of the DRD2 5′-regulatory region in sib pairs discordant for schizophrenia (Zhang et al. [@CR63]), a functional study of the *SLC12A6* promoter (Moser et al. [@CR45]), and a methylation-sensitive representational difference analysis of lymphoblastoid cells derived from monozygotic twins noted above (Kuratomi et al. [@CR31]), the report on *BDNF* methylation in unipolar depression noted above (Fuchikami et al. [@CR17]), and the investigation of BD (D\'Addario et al. [@CR9]). Another limitation is that the approach we used, namely bisulfite conversion-based analysis, is not able to differentiate 5-methyl cytosine (5-mC) from 5-hydroxymethyl cytosine (5-hmC) and unmodified cytosine from 5-formyl cytosine (5-fC) plus 5-carboxylcytosine (5-caC). A final limitation is that medication effects may be causing false positive results; we lacked the required current mood stabilizer data to characterize such potential influences on methylation.

Here, we also report exploratory *post hoc* results showing that a majority (4/5) of the FDR-significant methylation signals from the initial analysis were statistically significant in rs6265 Val homozygotes (GG) and not in Met carriers (AG+AA). Although the findings are not without some ambiguity, they are suggestive of SNP-methylation interactions.

Meta-analysis of the original 14 published studies of rs6265 in BD, including family-based and case--control designs, showed moderate nominal association for rs6265 - specifically the G(Val) allele was associated with BD. Though much evidence points to the rare Met allele having deleterious cognitive effects, there has been curiosity why the common Val allele is the one associated with BD (Fan and Sklar [@CR13]). Our preliminary results in this small sample, if confirmed by replication, suggest rs6265 SNP-promoter methylation interactions may be measurable in BD.

Conclusions {#Sec17}
===========

The sample size is small and therefore underpowered to draw firm conclusions. Our results add to a growing literature on *BDNF* methylation in BD by the use of precise mass spectrometry assays of CpGs in previously uninvestigated *BDNF* promoters in one of the largest BD epigenetics samples of peripheral tissue to date; they underscore the complexity of *BDNF* regulation across nine functional promoters and multiple transcripts and altogether suggest a need for more comprehensive epigenetic investigation of the locus.
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